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 28 
Abstract 29 
Endometriosis is currently defined as presence of endometrial epithelial and stromal cells at ectopic 30 
sites. This simple and straightforward definition has served us well since its original introduction. 31 
However, with advances in disease knowledge, endometrial stromal and glands have been shown to 32 
represent only a minor component of endometriotic lesions and they are often absent within some 33 
disease forms.  In rectovaginal nodules, the glandular epithelium is often not surrounded by stroma 34 
and frequently no epithelium can be identified in the wall of ovarian endometriomas. On the other 35 
hand, a smooth muscle component and fibrosis represent consistent features of all disease forms. 36 
Based on this facts, we believe that the definition of endometriosis should be reconsidered in terms 37 
of ‘A fibrotic condition in which endometrial stroma and epithelium can be identified’. The main 38 
reasons for this change are: 1. to foster the evaluation of fibrosis in studies on endometriosis 39 
pathogenesis using animal models; 2. to potentially limit false negative diagnoses if pathologists 40 
stringently stick to the current definition of endometriosis requiring the demonstration of 41 
endometrial stromal and glands; 3. to consider fibrosis as a potential target for treatment in 42 
endometriosis. This introductory discussion article is aimed at boosting up the attention to a largely 43 
neglected aspect of the disease. Hopefully, targeting the fibrotic process might also reduce the high 44 
attrition rate observed for new therapeutic approaches during the last decades. 45 
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Introduction 54 
With advances in knowledge, borders of diseases may change. Occasionally, these changes 55 
are of such a magnitude that they require a redefinition of the disease. Also in endometriosis, since 56 
the original description by John A. Sampson in 1927, there have been radical changes in our vision 57 
of the disease, starting with a better description of the various manifestations and more specific 58 
pathologic findings. Moreover, our understanding continues to ameliorate with increasing 59 
knowledge of genetics and risk factors and progresses in biological mechanisms and animal models 60 
of the disease. With these advances, clinicians and specialists in genetics, epidemiology, pathology 61 
and basic science have developed their own conceptualizations of endometriosis which is much 62 
more than the current simplistic definition that is based on the mere presence of endometrial 63 
epithelial and stromal cells in ectopic sites.  64 
Some main issues were indeed identified to challenge this obsolete definition. Even if the 65 
presence of endometrial stromal and glands may be the starting point of the whole process leading 66 
to endometriosis, it is unquestionable that endometrial stromal and glands represent only a minor 67 
component of endometriotic lesions. Most importantly, this classical pathologic substrate may even 68 
lack. In rectovaginal nodules, the glandular epithelium can often be observed deeply in the 69 
fibromuscolar tissue without any surrounding stroma (Donnez et al., 1995), and in 40% of ovarian 70 
endometriomas, no endometrial epithelium can be identified and the inner surface of the cyst is 71 
covered only by fibrotic tissue (Muzii et al., 2007). Finally, pelvic adhesions are typically free of 72 
endometrial components despite being an essential pathologic characteristic of the disease 73 
(Somigliana et al., 2012). Noteworthy, pelvic adhesions may contribute to the determinism of some 74 
classical endometriosis-related symptoms, such as deep dyspareunia, chronic pelvic pain and 75 
infertility, and may play a role in the formation of endometriomas or deep nodules (Somigliana et 76 
al., 2012). This opinion paper is intended as an introductory discussion article, an opening of 77 
dialogue in order to consider some changes in the general definition of endometriosis. The need for 78 
a modification is also supported by previous attempts in this context (Holt and Weiss, 2000). We 79 
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will herein emphasize the consistent presence of fibrosis and myofibroblasts in endometriotic 80 
lesions and their crucial role in the pathogenesis of the disease (Anaf et al., 2000; Barcena de 81 
Arellano et al., 2011; Zhang et al., 2016). Highlighting these features is aimed at boosting up the 82 
attention of the scientific community to a largely neglected but essential disease aspect. Ultimately, 83 
an enhanced sensitivity to fibrosis may orient the focus of researchers towards a more modern and 84 
realistic vision of endometriosis, could the current animal models to the real nature of the disease, 85 
may open new and more fruitful avenues of pharmacological  research and may reduce the high 86 
attrition rate observed for new therapeutic approaches of endometriosis during the last decades 87 
(Vercellini et al., 2011). 88 
 89 
The biological basis of fibrosis development: the crucial role of myofibroblasts 90 
Myofibroblasts are contractile non-muscle cells that are usually activated in response to 91 
injury with the intent to repair damaged extracellular matrix (ECM). These cells can differentiate 92 
from different cellular lineages including tissue resident fibroblasts, endothelial cells undergoing 93 
endothelial-to-mesenchymal transition, vascular smooth muscle cells and epithelial cells after 94 
epithelial-to-mesenchymal transition. A myofibroblast is activated when the α-smooth muscle 95 
isoform of actin (α-SMA) is neo-expressed and incorporated in stress fiber-like bundles which are 96 
pivotal to promote the specific myofibroblast function of contracting the ECM. Two factors seem 97 
critical to activate myofibroblasts from various precursor cells in the vast majority of organs 98 
studied: Transforming Growth Factor (TGF)-β and the stiffness of the tissue. Indeed, TGF-β1 is 99 
able to induce neo-expression of α-SMA by fibroblasts in vivo and in vitro and cultures on stiff 100 
substrates such as a fibrotic scar can activate a variety of different progenitors to become 101 
myofibroblasts (Richter et al., 2015; Hinz, 2016a).  102 
When activated, myofibroblasts display increased proliferation, migratory ability, 103 
production of cytokines and interstitial matrix with the consequence of disrupting the function of 104 
intact residual tissues and altering the biochemical and biophysical microenvironment. A persistent 105 
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myofibroblast activity causes accumulation and contraction of collagenous ECM, a condition called 106 
fibrosis. Macroscopically, due to accumulation of ECM, contraction of myofibroblasts and reduced 107 
vasculature, fibrotic organs usually display an uneven surface, are pale and not elastic. This process 108 
ultimately results in disruption of the normal anatomical structure (Bochaton-Piallat et al., 2016). 109 
Myofibroblasts are present in all fibrotic diseases, such as scleroderma, as well as liver, kidney, and 110 
lung fibrosis and are prominent in heart failure and repair after myocardial infarction (Rockey et al., 111 
2015; Chistiakov et al., 2016). Myofibroblast-produced tissue contractures can become life-112 
threatening when fibrosis affects vital organs (Rockey et al., 2015). 113 
Discriminating between myofibroblasts and smooth muscle cells may be demanding and 114 
may be a matter of controversy (Hinz, 2016a). Neo-expression of α-SMA in stress fibers is the most 115 
commonly used molecular marker for myofibroblasts that also express mesenchymal marker 116 
proteins such as N-cadherin, vimentin and S1004A. However, these latter markers are also 117 
expressed in smooth muscle cells, at least during tissue repair. Smooth muscle cells conversely 118 
express a number of late differentiation markers, such as smooth muscle myosin heavy chain, h-119 
caldesmon, smoothelin and the muscle intermediate filament protein desmin, that are absent from 120 
myofibroblasts in most organs. However, discriminating smooth muscle cells from myofibroblasts 121 
is quite difficult in pathological conditions, so their distinction is usually a rather semantic issue 122 
(Hinz, 2016a). Noteworthy, a metaplastic transformation from stromal cells to smooth muscle cells 123 
via differentiation from fibroblasts to myofibroblasts has been also suggested (Zhang et al., 2016). 124 
Not surprisingly, the interest of researchers in various fields of medicine has recently 125 
focused on anti-fibrotic therapeutic strategies aimed at blocking cytokines and factors that directly 126 
control myofibroblast activation (Yang et al., 2014). The complex presentation and activation 127 
mechanisms of TGF-β1 have led to develop various anti-TGF-β1 approaches to prevent 128 
myofibroblast formation and fibrosis development. Some initial findings were disappointing in 129 
terms of both efficacy and safety. However, clinical trials using different anti-TGF-β1 treatments 130 
are ongoing in various diseases. Interestingly, since all the αv integrins have been shown to be able 131 
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to activate TGF-β1 and are expressed in a tissue- and cell-distinctive manner, inhibiting their TGF-132 
β1 activating function may be biologically more specific compared to the global inhibition of TGF-133 
β1 itself. Some anti-integrin molecules are currently under investigation in clinical trials to treat 134 
patients with lung fibrosis and initial findings seem promising (Hinz et al., 2016b). 135 
 136 
Fibrosis and myofibroblasts in endometriotic lesions 137 
Peritoneal lesions 138 
The first study on peritoneal endometriosis with a monoclonal antibody against α-SMA was 139 
published back in 1996 by Khare et al. (1996) who used immunoperoxidase and Masson’s trichome 140 
stains to determine respectively the presence of myofibroblasts and collagen in 10 pelvic wall 141 
samples. Well-formed smooth muscle bundles and dense type I collagen were found in these 142 
lesions. In 2000, Anaf and coworkers (2000) demonstrated by immunohistochemistry that all the 21 143 
peritoneal lesions considered were variably but consistently positive for α-SMA staining, whereas 144 
unaffected peritoneum and eutopic endometrial biopsies were negative. In 2002, Leyendecker et al. 145 
analyzed 35 endometriotic lesions with specific α-SMA antibody by immunohistochemistry and all 146 
of them stained positively for the marker. Although the authors did not formally discriminate 147 
between various disease forms, they clearly showed representative sections of peritoneal 148 
endometriotic lesions stained for α-SMA. The group of Sylvia Mechsner similarly evaluated 149 
peritoneal endometriosis specimens in two different studies. In the first one, 76% of 120 lesions 150 
showed α-SMA expression (2005) while in the second one, all 60 lesions showed positivity (2011). 151 
Therefore, smooth muscle content seems to represent an important and consistent feature of 152 
peritoneal endometriosis lesions. 153 
Interestingly, TGF-β1 levels were found to be significantly increased in the peritoneal fluid 154 
of women with peritoneal lesions compared to women without the disease. Exposure of mesothelial 155 
cells to TGF-β1 increased the production of lactate, with reduction in the local pH. This increase in 156 
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the amount of lactate resulted in acid activation of the TGF-β ligand with secondary induction of 157 
myofibroblast differentiation (Young et al., 2014). 158 
 159 
Ovarian cysts 160 
The fact that fibrosis is present in the ovarian cyst wall is well known. The cysts 161 
pseudocapsule is actually mostly constituted of fibrotic tissue. Noteworthy, the inner surface of the 162 
cyst is usually not entirely covered by an endometrial lining and when the endometrial lining is 163 
missing, only fibrotic tissue is identifiable. Positive immunostaining for α-SMA antibody was 164 
demonstrated in all of 10 and 13 ovarian cysts by Khare et al. (1996) and Anaf et al. (2000), 165 
respectively. According to Mechsner and coworkers (2005), who evaluated 40 ovarian lesions, the 166 
smooth muscle content was present in 87% of the cases. Liu et al. (2017) investigated the histologic 167 
features of deep and ovarian endometriotic lesions and observed a higher fibrotic content in the 168 
former compared with the latter lesion type. Still, the 25 ovarian samples consistently showed 169 
markers of fibroblast-to-myofibroblast transdifferentiation and stained positively for fibrosis at 170 
Masson’s trichrome technique. 171 
Fibrosis was also identified in ovarian cortex surrounding the endometrioma. Indeed, 172 
follicular density was found to be lower in the ovarian cortex adjacent to the endometriotic cyst and 173 
this phenomenon is thought to be associated with tissue alterations, such as formation of fibrosis 174 
and vascular deficiency, and does not seem to be related to mere mechanical stretching. Kitajima et 175 
al. (2014) compared the histologic features in apparently normal ovarian cortical tissue from ovaries 176 
with small endometriomas and from the contralateral healthy ovaries. Fibrosis, as determined by 177 
Masson’s trichrome staining with methyl green, was significantly more frequent in cortex from 178 
ovaries with endometriomas (80%) than in those without (27%) and the presence of fibrosis with 179 
concomitant loss of cortex-specific stroma was observed in 55% of cortical samples from ovaries 180 
with endometriomas but in none of those from contralateral healthy ovaries. 181 
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Interestingly, the group of Sun-Wei Guo has recently shown that, in cells derived from 182 
ovarian endometriosis, activated platelets promoted epithelial to mesenchymal transition, fibroblast-183 
to-myofibroblast transdifferentiation and differentiation to smooth muscle cells, resulting in 184 
increased cell contractility, collagen production and ultimately to fibrosis, via the release of TGF-β1 185 
and the induction of TGF-β/Smad signaling pathway. TGF-β1 blockade could reverse these 186 
phenomena (Zhang et al., 2016). 187 
 188 
Deep infiltrating endometriosis 189 
Donnez and coworkers (1995) demonstrated for the first time that deep endometriotic 190 
nodules were histologically composed of scanty stroma and glandular epithelium disseminated in 191 
extensive fibromuscular tissue. Gömöritrichrome stain was used to detect muscle tissue. They 192 
speculated that this smooth muscle content pre-existed in the correspondent normal area and was 193 
invaded by the ectopic endometrium. Subsequently, Anaf et al. (2000) based on the evaluation of 12 194 
rectovaginal nodules and eight uterosacral lesions consistently positive for an anti-α-SMA antibody, 195 
disputed the pre-existence of smooth muscle tissue in the rectovaginal nodules and conversely 196 
supported a trans-differentiation of endometrial stromal cells. Itoga and coworkers (2003) examined 197 
90 rectovaginal nodules for the presence of fibrosis by elastic-van Gieson staining of collagen and 198 
for positivity to anti-α-SMA and anti-desmin antibodies. Fibrosis was observed in all but one of the 199 
samples, and immunoreactivity for smooth muscle actin and desmin was observed in 89% of the 200 
specimens. In deep nodules (n=20), staining levels for α-SMA, desmin, collagen I and extent of 201 
fibrosis were shown to be higher than those of ovarian disease (Liu et al., 2017). van Kaam et al. 202 
(2008) not only showed that all the 20 deep infiltrating endometriotic lesions studied comprised 203 
fibromuscular tissue containing α-SMA-, desmin- and myosin-positive myofibroblastic cells, but 204 
again raised reasonable doubts on the origin of this muscle content. Indeed, they demonstrated that 205 
the inoculation of human endometrium into a nude mouse could induce α-SMA expression in the 206 
surrounding murine tissue. This would suggest that a reaction of the local environment to the 207 
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presence of ectopic endometrium, rather than the stromal differentiation toward smooth muscle 208 
cells, could be at the basis of fibrosis development. 209 
In spite of the identification of a fibrotic component in deep infiltrating disease, Matsuzaki 210 
and coworkers (2017) showed that the TGF-β1 signaling may be absent when culturing 211 
endometriotic cells taken from this type of lesions. They suggested that endometrial stromal cells 212 
from patients affected might differentiate into myofibroblasts without TGF-β1 treatment and 213 
produce collagen type I. Increased stiffness through increased myofibroblast collagen production 214 
may then further increase matrix stiffness resulting in a fibrotic environment in deep disease over 215 
time. 216 
 217 
Summary of the literature overview 218 
Regardless of the different hypotheses provided to explain the origin of myofibroblasts and 219 
fibrosis in endometriotic lesions (summarized in Figure 1) (Young et al., 2014; Zhang et al., 2016; 220 
Matsuzaki et al., 2017 Albertsen and Ward, 2017), all investigators agree on the predominance of 221 
this component. One may argue that fibrosis represents a secondary event triggered by an insult (the 222 
presence of ectopic cells) in a suffering tissue (Walton et al., 2017). However, fibrosis appears as 223 
the phenomenon underpinning endometriosis-associated morbidity and some manifestations of the 224 
disease (i.e. adhesions). Thus, in line with what is recognized for other conditions of unknown 225 
etiology such as scleroderma (Tsou et al., 2017), fibrosis seems to represents a self-amplifying 226 
event of endometriosis.  227 
 228 
Why changing the definition  229 
There are essentially three reasons for including the term "fibrosis" in the definition of 230 
endometriosis:  231 
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1. Myofibroblasts and fibrosis may receive more attention as potential targets of medical 232 
treatments for endometriosis. Shifting the focus on fibrosis with a new definition may re-233 
orient current research efforts towards more effective therapies. When considering the 234 
challenges of treating a fibrotic disease such as endometriosis, there is a pressing need to 235 
identify effective pharmacological agents to block fibrosis, in addition to seek for agents 236 
acting on ectopic endometrium (Somigliana et al., 2012). When investigating the effects of 237 
drugs interfering with endometrial tissue, researchers should concomitantly evaluate also the 238 
impact on fibrosis. Moreover, the scientific community should pay utmost attention to the 239 
progress on the management of fibrosis in other areas of medicine. If in the future some 240 
effective and safe antifibrotic drugs will be developed for other disorders, endometriosis 241 
might benefit as well. 242 
2. Given the consistent presence of myofibroblasts and fibrosis in all disease forms, animal 243 
models of endometriosis should also present this feature. The current definition could lead 244 
researchers astray in this regard, as they tend to consider an animal model reliable merely 245 
because endometrium is placed in at ectopic sites. However, endometriosis is much more 246 
than that and fibrosis represents a crucial histological aspect. Mouse, hamster or rat models 247 
have been developed so far by intraperitoneal or subcutaneous transplantation of autologous 248 
endometrial tissue from the same or syngeneic donors, or from humans in nude mice. 249 
“Endometriosis” is often induced surgically by suturing fragments of uterine tissue onto the 250 
peritoneum or, in mice, an alternative procedure is to simply inject fragments of minced 251 
uterine horns from donor mice into the peritoneum of recipient animals (Mariani et al., 252 
2012; Greaves et al., 2017). A great variety of compounds with different functional 253 
activities have been used in these models, and many of them have shown various degrees of 254 
inhibition of lesion growth (Bedaiwy et al., 2017). Unfortunately, to date, translation of 255 
these findings to the clinic has been limited, with some paradoxical but enlightening results. 256 
Raloxifene, for instance, was repeatedly demonstrated to be effective in rodent models 257 
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(Altintas et al., 2010) but, when tested in women in a RCT, it even accelerated pelvic pain 258 
recurrence after surgery when compared to placebo (Stratton et al., 2008).  A possible 259 
explanation could be the poor alignment of the outcome measures evaluated in the current 260 
animal models to the real nature of the disease. Disease features in an animal model should 261 
also include the evaluation of fibrosis presence that can be done in several ways (Kushiyama 262 
et al., 2011; Dong et al., 2017; Rittié et al., 2017) (Figure 2). 263 
3. A modification in the definition of endometriosis would not only aim at driving research 264 
towards more successful therapies, but may also have some immediate clinical implications. 265 
Indeed, from a diagnostic standpoint, based on histologic findings, endometriotic lesions can 266 
sometimes be misjudged. Some cases of endometriosis-related extensive pelvic adhesions 267 
may paradoxically remain without a definite diagnosis or erroneously considered long-term 268 
consequence of pelvic inflammatory disease (PID). This may be particularly true in the 269 
absence of endometriomas or deep peritoneal lesions and/or when surgical access to pelvic 270 
organs at surgery is impeded by the severity of the adhesions. In fact, extending the 271 
definition of endometriosis beyond the mere presence of ectopic endometrial tissue would 272 
consent to classify women with extensive pelvic adhesions and without evidence of past 273 
pelvic insults (such as for instance a damage of the tubal mucosa) as affected even in 274 
absence of the two classic components of the histologic diagnosis, i.e., endometrial stroma 275 
and glands. Noteworthy, even when available, surgical specimens are rarely serially 276 
sectioned in standard practice, and lesions with no or only small areas with endometrial 277 
lining can be missed by pathologists (Nisenblat et al., 2016). False negative diagnoses can 278 
occur if pathologists stringently stick to the current definition of endometriosis requiring the 279 
concurrent demonstration of both endometrial stroma and glands. With a cautious approach 280 
in order not to increase false positive cases, the definitive recognition of fibrosis as an 281 
essential component of endometriosis may overcome these uncertainties. Noteworthy, the 282 
debate on the reliability of non-invasive diagnosis of endometriosis may also be influenced 283 
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by a change in the definition of endometriosis. For instance, one cannot exclude that the 284 
current high accuracy of transvaginal ultrasound for the diagnosis of endometriomas 285 
(sensitivity of 93% and specificity of 94%) (Nisenblat et al., 2016) may improve if the 286 
definition of endometriosis will be modified. Sensitivity in particular may increase and 287 
transvaginal ultrasound could reach the requirements to become a replacement test 288 
(sensitivity ≥ 94% and specificity ≥79%) and thus definitively substitute laparoscopy for the 289 
diagnosis of these lesions. Noteworthy, for some fibrosis-based conditions such as 290 
retroperitoneal fibrosis, the diagnosis relies more upon the typical imaging features on CT or 291 
MRI, than on percutaneous biopsy (Cohan et al., 2017). 292 
 293 
Conclusions 294 
The present definition of endometriosis based on the histologic feature of the concomitant presence 295 
of endometrial stroma and epithelium in ectopic sites has been developed in order to guarantee a 296 
uniform identification of the condition. However, with the increasing knowledge of the disease 297 
mechanisms and the improvement of the diagnostic tools, this definition nowadays appears too 298 
simplicistic to represent the different histologic forms and clinical manifestations of this complex 299 
disease. Therefore, if on the one hand the identification of the specific histopathologic 300 
characteristics remains extremely important to diagnose endometriosis, on the other hand other 301 
aspects need to be broadened from both a diagnostic and a therapeutic point of view. In our view, 302 
the endometriosis definition should be reconsidered. ‘A fibrotic condition in which endometrial 303 
stroma and epithelium can be identified’ could represent a realistic starting point.  304 
 305 
 306 
 307 
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Figure legends 417 
 418 
Figure 1.  Main pathogenetic models proposed to explain the presence of myofibroblasts and 419 
the development of fibrosis in endometriosis. Epithelial to mesenchymal transition, fibroblast-to-420 
myofibroblast transdifferentiation, increased collagen production and ultimately fibrosis have been 421 
suggested to be triggered in endometriotic cells in presence of stimulating factors (B and C, 422 
platelets or a stiff tissue). Similar phenomena in other tissues (A, surrounding connective tissue or 423 
C, mesothelial barrier) have been also proposed. 424 
 425 
Figure 2. Sirius red staining of an ectopic endometrial tissue in the mouse to visualize the area 426 
occupied by fibrous collagen and usually used to assess a fibrotic phenomenon (Kushiyama et al., 427 
2011; Rittié et al., 2017). Left panels, magnification 2.5X; right panels, magnification 16X. 428 
 429 
